2026-06-24T14:49:28.213Z / 路透社
作者：迪娜·比斯利
2026年6月24日 世界标准时间14:49，1小时前更新
2020年8月29日，美国马里兰州怀特奥克的美国食品药品监督管理局（FDA）总部外的标识牌。路透社/安德鲁·凯利 获取授权许可，将在新标签页打开
美国食品药品监督管理局
6月24日（路透社）—— FDA代理专员办公室主任洛厄尔·泽塔周二在圣地亚哥举行的BIO国际大会上表示，去年裁员逾3000人的美国食品药品监督管理局已获授权招聘2200人。
此次裁员是卫生部长小罗伯特·F·肯尼迪重塑联邦公共卫生机构计划的一部分。
订阅《每日案卷》新闻简报，将最新法律新闻直接发送至您的收件箱，开启您的晨间资讯。点击此处注册。
前FDA官员去年曾警告称，裁员可能会扰乱该机构审查新药申请的能力。一些员工表示，由于裁员，他们难以按时完成国会规定的工作任务。
“我们将先召回2200人，”泽塔说。他表示，约600名新员工正在入职流程中，另有数百人已开始新工作。
此次招聘热潮之际，该机构宣布将采用更灵活的细胞和基因疗法生产方式，并公布了一项加快药物早期开发的新计划。FDA还同意重新评估此前拒绝批准的多款罕见病药物。
“我们的执行方式已经有所改变，”泽塔说道。
前FDA局长马蒂·马卡里于5月辞职，此前他与白宫高级官员和卫生顾问发生了数周的争执，并因一系列有争议的机构决策受到审查。
“我们收到了大量求职申请，”FDA生物制品评估和研究中心代理主任卡里姆·米哈伊尔说道。他表示，该机构还采取措施防止现有员工离职。
“我们付出了大量努力来降低人员流失率，”他说。米哈伊尔表示，在某些情况下，工作人员会被临时从一个部门调往工作量更大的另一个部门。
FDA药物评估和研究中心代理主任迈克尔·戴维斯表示，员工士气有所改善。
“我确实认为情况正在朝着正确的方向发展，”他说。“人员流失率已降至历史平均水平。”
戴维斯和其他FDA官员表示，他们正在做更多工作，将患者需求纳入药物审评流程，尤其是针对患者群体极小的病症。
“罕见病是一项未被满足的医疗需求，”泽塔说。“我认为这是一个重点关注领域。”
本文由迪娜·比斯利报道；安德烈亚·里奇编辑
我们的标准：路透社信托原则，将在新标签页打开
US FDA officials say hiring picks up speed with more than 2,000 jobs to start
2026-06-24T14:49:28.213Z / Reuters
By Deena Beasley
June 24, 2026 2:49 PM UTC Updated 1 hour ago
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly Purchase Licensing Rights, opens new tab
U.S. Food and Drug Administration
June 24 (Reuters) – The U.S. Food and Drug Administration, which cut more than 3,000 employees last year, has been authorized to hire 2,200 people, Lowell Zeta, acting chief of staff for the FDA commissioner, said on Tuesday at the BIO International Convention in San Diego.
The cuts were part of efforts by Health Secretary Robert F. Kennedy Jr. to reshape federal public health agencies.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Former FDA officials warned last year that the job reductions could disrupt the agency’s ability to review applications for new medicines. Some staffers said they were struggling to meet deadlines mandated by Congress due to the layoffs.
“We are going to bring back 2,200, to start,” Zeta said. He said around 600 new employees are in the process of onboarding and a couple hundred have started their new jobs.
The hiring spree comes as the agency said it will use a more flexible, opens new tab approach to manufacturing of cell and gene therapies and announced a new plan to speed early drug development. The FDA has also agreed to reassess several drugs for rare diseases that it had previously declined to approve.
“Our execution has changed a bit,” Zeta said.
Former FDA Commissioner Marty Makary resigned from the post in May after weeks of clashing with top White House and health advisers and drawing scrutiny for a series of controversial agency decisions.
“We are seeing very significant numbers applying,” said Karim Mikhail, acting director of the FDA’s Center for Biologics Evaluation and Research. He said the agency is also taking actions meant to stop current employees from leaving their jobs.
“There is a lot of effort to minimize attrition,” he said. In some cases, Mikhail said, staff are being temporarily transferred from one department to another where the workload may be higher.
Michael Davis, acting director at the FDA’s Center for Drug Evaluation and Research, said staff morale has been improving.
“I do feel that things are moving in the right direction,” he said. “Attrition is down to the historic rate.”
Davis and the other FDA officials said more work is being done to include patient needs in the drug review process, particularly for conditions with very small patient populations.
“Rare disease is an unmet need,” Zeta said. “I think that is a big focus.”
Reporting by Deena Beasley; Editing by Andrea Ricci
Our Standards: The Thomson Reuters Trust Principles., opens new tab